VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
VistaGen Therapeutics, Inc. (VTGN) reported a Q3 loss of $0.46 per share, which was better than the Zacks Consensus Estimate of a $0.50 loss. However, this is a larger loss compared to $0.22 per share a year ago.
February 14, 2025 | 12:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VistaGen Therapeutics reported a Q3 loss of $0.46 per share, better than the expected $0.50 loss but worse than last year's $0.22 loss. This mixed result may lead to short-term volatility in VTGN's stock price.
The earnings report shows a better-than-expected loss, which is positive, but the increased loss compared to last year is negative. This mixed result could lead to short-term volatility in the stock price as investors digest the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100